CONCLUSIONS
NSCLC
NSCLC
Toripalimab combined with anlotinib was tolerable in patients with EGFR‐TKI‐resistant advanced NSCLC who had not previously received chemotherapy, but this combination model therapy did not achieve the expected efficacy. Patients without detectable 